background
viral
upper
respiratori
tract
infect
occur
frequent
among
conscript
probiot
reduc
viral
infect
children
attend
day
care
limit
data
avail
effect
probiot
nasopharyng
presenc
respiratori
virus
object
assess
whether
probiot
could
decreas
nasopharyng
occurr
respiratori
virus
finnish
conscript
studi
design
random
doubleblind
placebocontrol
intervent
studi
nasopharyng
swab
sampl
collect
symptomat
conscript
receiv
daili
chewabl
probiot
tablet
contain
lactobacillu
rhamnosu
gg
bifidobacterium
animali
ssp
lacti
control
tablet
visit
garrison
health
care
center
due
symptom
infect
presenc
respiratori
virus
test
pcrmethod
viral
find
compar
intervent
group
result
nasopharyng
sampl
posit
least
one
respiratori
viru
picornavirus
common
virus
detect
sampl
rhinovirusposit
enterovirusposit
control
group
probiot
group
picornaviru
infect
p
monthli
distribut
picornavirus
show
less
picornaviru
find
month
probiot
group
control
group
p
howev
probiot
reduc
picornaviru
occurr
month
conclus
overal
probiot
reduc
viral
occurr
symptomat
conscript
howev
probiot
decreas
presenc
picornavirus
month
may
impli
probiot
play
role
virus
caus
common
cold
investig
necessari
clarifi
mechan
involv
order
target
specif
probiot
specif
respiratori
virus
common
ill
human
acut
respiratori
tract
infect
rti
major
common
cold
acut
rti
also
lead
caus
miss
day
servic
among
militari
conscript
annual
approxim
conscript
train
finland
garrison
around
finland
upper
rti
case
maxillari
sinu
infect
middl
ear
infect
diagnos
moreov
approxim
case
bronchiti
pneumonia
report
militari
traine
especi
high
risk
epidem
respiratori
infect
due
crowd
live
condit
barrack
environment
factor
physic
stress
relat
militari
train
viru
type
known
caus
acut
rti
frequent
caus
agent
common
cold
rti
vari
sever
human
rhinovirus
rv
current
effect
antivir
vaccin
prevent
treatment
respiratori
viru
infect
avail
influenza
virus
addit
adenoviru
vaccin
serotyp
avail
us
armi
howev
common
cold
rv
virtual
effect
treatment
medic
current
approach
prevent
viru
transmiss
avoid
close
contact
hand
hygien
probiot
defin
live
microorgan
confer
health
benefit
host
increas
evid
show
probiot
may
provid
protect
rti
case
viral
origin
use
specif
probiot
lactobacillu
l
rhamnosu
gg
bifidobacterium
b
animali
ssp
lacti
shown
promis
result
reduc
respiratori
symptom
ill
especi
children
moreov
combin
l
rhamnosu
gg
b
lacti
reduc
risk
durat
rti
children
young
adult
convinc
result
effect
probiot
viru
infect
studi
specif
probiot
allevi
durat
sever
acut
rotaviru
gastroenter
respiratori
viru
infect
howev
implic
probiot
may
reduc
viral
occurr
nasopharynx
aim
studi
investig
effect
regular
consumpt
probiot
combin
l
rhamnosu
gg
b
lacti
nasopharyng
occurr
respiratori
virus
two
conscript
group
suffer
respiratori
infect
attend
militari
servic
finland
juli
januari
studi
part
larger
random
doubleblind
placebocontrol
parallel
group
intervent
studi
investig
whether
l
rhamnosu
gg
b
lacti
decreas
infect
conscript
gulf
finland
naval
command
upinniemi
hamina
http
clinicaltrialsgov
identifi
kalima
et
al
manuscript
studi
conduct
accord
guidelin
laid
declar
helsinki
procedur
involv
human
subjectspati
approv
ethic
committe
helsinki
uusimaa
hospit
district
written
inform
consent
obtain
particip
origin
total
healthi
adult
age
year
mean
year
fulfil
inclus
criteria
kalima
et
al
manuscript
enrol
studi
two
intak
conscript
juli
recruit
end
octob
reserv
offic
candid
conscript
random
receiv
either
one
chew
tablet
orion
pharma
ltd
espoo
finland
contain
xylitol
sorbitol
microfibr
cellulos
magnesium
stearat
citru
flavor
n
control
group
tablet
cfu
l
rhamnosu
gg
atcc
cfu
b
animali
ssp
lacti
dsm
chr
hansen
hoersholm
denmark
n
probiot
group
twice
daili
either
juli
decemb
recruit
day
octob
januari
reserv
offic
candid
day
intervent
whenev
conscript
suffer
upper
rti
symptom
sought
treatment
garrison
healthcar
center
nasopharyng
swab
sampl
collect
flockedtip
nylon
swab
copan
diagnost
murrieta
ca
usa
insert
nasopharynx
nose
swab
place
immedi
vial
contain
ml
univers
transport
medium
utmrt
copan
diagnost
murrieta
ca
usa
store
c
xtag
respiratori
viru
panel
assay
viral
nucleic
acid
purifi
collect
swab
sampl
magna
pure
robot
roch
diagnost
ltd
unit
kingdom
accord
manufactur
instruct
human
rhino
rv
enteroviru
ev
pcr
assay
viral
nucleic
acid
purifi
describ
rvp
fast
assay
detect
follow
respiratori
virus
influenza
b
virus
respiratori
syncyti
virus
rsv
b
parainfluenzavirus
adenoviru
adv
human
metapneumoviru
hmpv
coronavirus
picornavirus
evrv
human
bocaviru
hbov
addit
assay
allow
subtyp
influenza
viru
season
virus
unsubtyp
influenza
viru
assay
perform
describ
earlier
briefli
total
nucleic
acid
sampl
store
c
isol
magna
pure
robot
roch
diagnost
ltd
extract
instantli
subject
rvp
fast
assay
luminex
molecular
diagnost
inc
toronto
canada
realtim
pcr
picornavirus
rv
ev
perform
nation
institut
health
welfar
describ
previous
curv
rise
threshold
consid
posit
realtim
assay
execut
analyz
stratagen
la
jolla
ca
usa
evalu
differ
number
subject
suffer
specif
viru
two
studi
group
nasopharyng
sampl
repres
one
viru
infect
conscript
first
analyz
separ
merg
analyz
togeth
viru
analys
perform
monthli
symptom
symptom
throughout
whole
period
independ
rel
small
sampl
size
appli
fisher
exact
test
conting
tabl
frequenc
distribut
get
viru
two
group
display
matrix
format
result
pvalu
consid
statist
signific
analys
conduct
use
r
version
r
foundat
statist
comput
tabl
monthli
distribut
collect
nasopharyng
swab
sampl
conscript
intervent
group
conscript
group
juli
januari
finland
total
nasopharyng
swab
sampl
collect
symptomat
conscript
control
group
probiot
group
visit
garrison
healthcar
center
intervent
period
least
one
nasopharyng
swab
sampl
collect
conscript
mean
rang
monthli
distribut
collect
nasopharyng
sampl
conscript
group
intervent
group
shown
tabl
collect
sampl
almost
equal
distribut
intervent
group
except
reserv
offic
candid
fewer
collect
sampl
decemb
januari
probiot
group
collect
nasopharyng
sampl
posit
least
one
respiratori
viru
coinfect
two
three
four
virus
found
sampl
studi
major
viru
contain
sampl
picornavirusposit
n
follow
human
coronavirus
n
piv
n
hmpv
n
adv
n
influenza
b
viru
n
influenza
viru
n
rsv
n
piv
hbov
detect
specimen
rv
ev
pcrscreen
picornavirusposit
sampl
reveal
picornavirusposit
sampl
rvposit
evposit
evposit
specimen
also
posit
rv
pcrassay
virus
detect
month
studi
picornavirus
preval
virus
juli
decemb
wherea
human
coronavirus
peak
januari
fig
tabl
show
distribut
detect
respiratori
virus
nasopharyng
sampl
conscript
group
intervent
group
overal
fewer
virus
detect
probiot
group
control
group
although
differ
statist
signific
probiot
decreas
total
number
picornavirus
rv
ev
recruit
reserv
offic
candid
conscript
group
combin
fig
show
distribut
respiratori
virus
intervent
group
nasopharyng
sampl
collect
symptomat
conscript
juli
januari
finland
statist
differ
viral
find
intervent
group
abbrevi
rsv
respiratori
syncyti
viru
adv
adenoviru
piv
parainfluenza
viru
rv
human
rhinoviru
ev
human
enteroviru
hmpv
human
metapneumoviru
recruit
reserv
offic
candid
total
p
p
monthli
distribut
picornaviru
find
intervent
group
militari
recruit
reserv
offic
candid
monthli
examin
picornaviru
posit
sampl
reveal
septemb
three
time
fewer
picornavirus
mainli
rv
probiot
group
p
fig
month
studi
signific
differ
picornaviru
posit
sampl
intervent
group
moreov
differ
probiot
control
group
monthli
distribut
respiratori
viru
find
studi
investig
whether
regular
consumpt
probiot
combin
lactobacillu
rhamnosu
gg
bifidobacterium
lacti
would
decreas
nasopharyng
occurr
respiratori
virus
conscript
attend
militari
servic
picornavirus
particular
rhinovirus
common
agent
found
symptomat
conscript
probiot
decreas
total
number
picornavirus
either
militari
recruit
reserv
offic
candid
howev
result
show
militari
recruit
receiv
probiot
significantli
fewer
picornavirus
month
intervent
septemb
reduc
effect
observ
month
studi
virus
either
militari
recruit
reserv
offic
candid
find
possibl
explain
fact
conscript
enrol
studi
differ
month
juli
vs
end
octob
therefor
differ
respiratori
virus
circul
popul
due
season
variat
addit
probiot
picornaviru
reduc
effect
month
intervent
impli
order
probiot
effect
suffici
prime
time
requir
otitispron
children
probiot
combin
also
abl
reduc
human
bocaviru
load
month
reason
reduc
effect
observ
virus
may
differ
probiot
strain
may
divers
antivir
mechan
awar
similar
clinic
studi
conduct
young
adult
investig
effect
probiot
nasal
occurr
respiratori
virus
clinic
studi
children
impli
specif
probiot
l
rhamnosu
gg
may
impact
reduc
occurr
respiratori
virus
healthi
children
attend
day
care
children
receiv
l
rhamnosu
gg
milk
seem
fewer
influenza
viru
upper
respiratori
tract
although
differ
statist
signific
probiot
control
group
otitispron
children
combin
probiot
includ
l
rhamnosu
gg
reduc
significantli
nasopharyng
presenc
human
bocaviru
dna
preterm
infant
l
rhamnosu
gg
reduc
significantli
incid
rhinovirusinduc
episod
howev
properti
probiot
speci
vari
highli
strain
specif
combin
probiot
may
differ
effect
singl
strain
probiot
may
mediat
antivir
effect
rhinovirus
possibl
enhanc
cellular
immun
airway
increas
activ
natur
killer
cell
macrophag
product
interferon
probiot
may
also
hinder
absorpt
rhinoviru
host
cell
via
bind
intercellular
adhes
instanc
macrophag
cell
cultur
l
rhamnosu
prevent
influenza
viru
replic
product
viral
protein
induc
type
interferondepend
gene
activ
mice
l
rhamnosu
gg
protect
influenza
viru
infect
enhanc
respiratori
cellmedi
immun
respons
tumor
necrosi
factor
monocyt
chemotact
upregul
lung
natur
killer
cell
rat
endotoxininduc
intestin
damag
bifidobacterium
infanti
decreas
express
intercellular
adhes
howev
mechan
behind
antivir
effect
l
rhamnosu
gg
b
lacti
rhinovirus
examin
preval
virus
studi
picornavirus
found
diverg
pcrdetect
picornavirus
xtag
respiratori
viru
panel
assay
rv
ev
separ
screen
assay
could
partli
explain
fact
util
pcr
assay
target
differ
gene
region
addit
possibl
natur
isol
ev
crossreact
noncod
regiontarget
primer
probe
use
rvspecif
realtim
rtpcr
assay
vice
versa
possibl
affect
result
final
identif
rv
ev
isol
execut
via
molecular
type
capsid
code
gene
respect
howev
present
confin
sensit
limit
use
type
assay
case
posit
find
high
c
valu
realtim
pcr
abund
picornaviru
rv
find
expect
rv
preval
caus
common
cold
particularli
earli
fall
detect
virus
among
adolesc
rv
present
studi
rv
detect
month
juli
januari
peak
occurr
juli
result
interest
light
previou
report
peak
preval
rv
infect
northern
hemispher
occur
autumn
spring
howev
rv
infect
also
detect
juli
finnish
militari
anoth
studi
although
detect
rate
much
lower
studi
find
present
studi
may
reflect
fact
larg
cohort
militari
recruit
enter
simultan
semiclos
environ
garrison
infect
spread
rapidli
due
high
infect
pressur
howev
type
data
proof
outbreak
rv
infect
caus
small
number
rv
type
recruit
period
juli
would
necessari
contrast
picornavirus
adenovirus
influenza
virus
found
commonli
among
militari
conscript
occur
present
studi
much
lower
preval
notic
howev
result
viral
find
slightli
bias
number
collect
nasopharyng
sampl
gradual
decreas
toward
end
studi
due
discontinu
conscript
intervent
trial
kalima
et
al
manuscript
influenza
season
finland
season
peak
januari
march
therefor
major
infect
miss
present
studi
acut
upper
respiratori
tract
infect
also
known
common
cold
mainli
caus
rhinovirus
due
mani
differ
serotyp
develop
vaccin
rhinovirus
unlik
prevent
clinic
use
measur
simpl
low
cost
without
advers
reaction
need
order
effect
control
infect
along
proper
hand
hygien
probiot
therapi
could
attract
safe
altern
prevent
allevi
rhinoviru
infect
present
studi
observ
fewer
picornavirus
predominantli
rhinovirus
nasopharyng
sampl
militari
conscript
month
use
probiot
l
rhamnosu
gg
b
lacti
howev
reduc
effect
seen
total
number
picornaviru
find
month
studi
studi
reveal
specif
antivir
mechan
probiot
l
rhamnosu
gg
b
lacti
rhinovirus
warrant
